Co-administration may lead to torsade de pointes-type ventricular tachycardia due to QT prolongation. Avoid concomitant use.
Source: NLP:macimorelin acetate
9 interactions on record
Co-administration may lead to torsade de pointes-type ventricular tachycardia due to QT prolongation. Avoid concomitant use.
Source: NLP:macimorelin acetate
Antiarrhythmic affected by clarithromycin CYP3A inhibition. Risk of QTc prolongation and torsades de pointes.
Source: NLP:clarithromycin
Proarrhythmic events more common with concurrent use. Increased risk of arrhythmias with concomitant administration.
Source: NLP:digoxin
Class III anti-arrhythmic drug that may increase risk of QT prolongation and Torsades de Pointes due to additive effects on heart rate and QT interval.
Source: NLP:etrasimod
Should be avoided due to risk of QT prolongation and torsades de pointes.
Source: NLP:foscarnet sodium
Class III antiarrhythmic that prolongs QTc interval. Concomitant use should be avoided due to additive QTc prolongation risk.
Source: NLP:tetrabenazine
Class 3 antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.
Source: NLP:haloperidol decanoate
Class 3 antiarrhythmic that prolongs QTc interval; caution advised when used with haloperidol due to risk of QT prolongation.
Source: NLP:haloperidol lactate
Class III antiarrhythmic drug; specific interaction studies not performed but caution is advised when used with lidocaine and prilocaine.
Source: NLP:lidocaine and prilocaine